Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenzilumab in Previously Treated CMML
NCT02546284Phase 1Completed
- Sponsor
- Humanigen
- Start
- Jul 2016
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenzilumab in chronic myelomonocytic leukemia (CMML), sponsored by Humanigen. Primary endpoint: Number of participants with adverse events at 12 months. Started Jul 2016; status: completed.
02
Drugs
lenzilumab
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02546284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546284.